PE ratio relative to earnings growth — is the valuation justified?
| Symbol | Company | PEG | P/E | Growth | vs AZN |
|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.12 | 17.8 | 149.5% | -43% |
| GSK | GSK plc | 0.99 | 14.3 | 14.4% | +375% |
| NVS | Novartis AG | 1.53 | 23.5 | 15.4% | +632% |
| LLY | Eli Lilly and Company | 1.55 | 42.6 | 27.5% | +641% |
| MRK | Merck & Co., Inc. | 1.74 | 36.8 | 21.2% | +732% |